Gargoyle Investment Advisor L.l.c. buys $4,179,373 stake in Baxter International Inc (BAX)

Baxter International Inc (BAX) : Gargoyle Investment Advisor L.l.c. scooped up 17,812 additional shares in Baxter International Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 9, 2016. The investment management firm now holds a total of 91,814 shares of Baxter International Inc which is valued at $4,179,373.Baxter International Inc makes up approximately 1.45% of Gargoyle Investment Advisor L.l.c.’s portfolio.

Other Hedge Funds, Including , Morgan Dempsey Capital Management added BAX to its portfolio by purchasing 45 company shares during the most recent quarter which is valued at $2,048.Profund Advisors reduced its stake in BAX by selling 3,355 shares or 11.68% in the most recent quarter. The Hedge Fund company now holds 25,378 shares of BAX which is valued at $1,143,786. Baxter International Inc makes up approx 0.06% of Profund Advisors’s portfolio.United Bank reduced its stake in BAX by selling 47,515 shares or 74.35% in the most recent quarter. The Hedge Fund company now holds 16,396 shares of BAX which is valued at $725,031. Baxter International Inc makes up approx 0.33% of United Bank’s portfolio.Aperio Group boosted its stake in BAX in the latest quarter, The investment management firm added 35,037 additional shares and now holds a total of 200,869 shares of Baxter International Inc which is valued at $8,882,427. Baxter International Inc makes up approx 0.08% of Aperio Group’s portfolio.

Baxter International Inc closed down -0.11 points or -0.24% at $45.52 with 2,48,74,078 shares getting traded on Friday. Post opening the session at $45.56, the shares hit an intraday low of $45.225 and an intraday high of $45.91 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.

On the company’s financial health, Baxter International Inc reported $0.36 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Apr 26, 2016. Analyst had a consensus of $0.29. The company had revenue of $2375.00 million for the quarter, compared to analysts expectations of $2351.22 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.00 EPS.

Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Apr 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 47 from a previous price target of $40 .Baxter International Inc was Upgraded by Piper Jaffray to ” Overweight” on Apr 14, 2016.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.

Leave a Reply

Baxter International Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxter International Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.